Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.55 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.55 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.55 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.55 |
| ▸ | PYGB | P11216 | 7/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20161462 | 0.85 | LGALS3 (0.46) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| SCHEMBL8720698 | 0.81 | LGALS3 (0.60) | LGALS3LGALS1LGALS9LGALS8PYGB | |
| SCHEMBL7997349 | 0.81 | LGALS3 (0.60) | LGALS3LGALS1LGALS9LGALS8PYGB | |
| SCHEMBL6424696 | 0.81 | LGALS3 (0.60) | LGALS3LGALS1LGALS9LGALS8PYGB | |
| SCHEMBL8720696 | 0.81 | LGALS3 (0.60) | LGALS3LGALS1LGALS9LGALS8PYGB | |
| SCHEMBL887998 | 0.81 | LGALS3 (0.60) | LGALS3LGALS1LGALS9LGALS8PYGB | |
| SCHEMBL7454325 | 0.81 | LGALS3 (0.60) | LGALS3LGALS1LGALS9LGALS8PYGB | |
| SCHEMBL20161575 | 0.79 | LGALS3 (0.62) | LGALS3LGALS1LGALS9LGALS8PYGB | |
| SCHEMBL20161475 | 0.79 | LGALS3 (0.62) | LGALS3LGALS1LGALS9LGALS8PYGB | |
| SCHEMBL20161631 | 0.77 | LGALS3 (0.44) | LGALS3LGALS1LGALS9LGALS8PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045411-B2 | Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same | L'OREAL (FR) | 2021-06-29 | — | — | US | disclosed |
| US-20180133137-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | L'OREAL (FR) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133137-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | KRT18, CUTA, GLA | LGALS3 403/4885LGALS1 408/4885LGALS9 567/4885 |
| US-11045411-B2 | Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same | KRT18, CUTA, GLA | LGALS3 403/4885LGALS1 408/4885LGALS9 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.